Premium
Association between myocarditis and other immune‐related adverse events secondary to immune checkpoint inhibitor use
Author(s) -
Guha Avirup,
AlKindi Sadeer,
Jain Prantesh,
Tashtish Nour,
ElAmm Chantal,
Oliveira Guilherme H.
Publication year - 2020
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.32960
Subject(s) - medicine , atezolizumab , common terminology criteria for adverse events , meddra , pembrolizumab , adverse effect , durvalumab , nivolumab , ipilimumab , myocarditis , adverse event reporting system , odds ratio , pharmacovigilance , oncology , cancer , immunotherapy